Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

Signature(s)

Amount
€ 100,000,000
Countries
Sector(s)
Hungary : € 100,000,000
Industry : € 100,000,000
Signature date(s)
24/09/2009 : € 100,000,000
Link to source
Other links

Summary sheet

Release date
3 March 2009
Status
Reference
Signed | 24/09/2009
20080302
Project name
Promoter - financial intermediary
Debrecen Pharma R&D (RSFF)

The promoter is one of the top 20 pharmaceutical companies in the world and the largest generic pharmaceutical company.

Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 100 million.
EUR 200 million.
Location
Sector(s)
Description
Objectives

The project concerns financing the R&D for new Active Pharmaceutical Ingredients (APIs), innovative drug compounds and new generic drugs located in Debrecen, Gödöllö and Sajobabony, as well as two related capital expenditure investments in R&D Centres in Debrecen and Gödöllö.

The aim of the first, R&D part of the project is the commercialisation of more than 30 new generic compounds up to 2013. The purpose of the capital expenditure investments is to increase the existing R&D infrastructure.

Environmental aspects
Procurement

Installations for the R&D Centre in Debrecen will fall under Annex II of the EIA Directive 85/337/EEC, amended by Directives 97/11/EC and 2003/35/EC. Whether the competent authorities have required an EIA or not will be verified during appraisal, as well as any actual/possible significant impacts on protected flora and fauna (Habitats and Birds Directives). Compliance of R&D activities with relevant EU legislation in regards to animal testing, clinical trials, etc. will be verified during appraisal.

The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives 2004/18/EC. The promoter carries out competitive international consultations among potential suppliers for goods and services, which is standard practice for this industry.

Link to source
Other links

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

Related publications